Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

ClinicalTrials.gov ID: NCT00244595

Public ClinicalTrials.gov record NCT00244595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objectives of this study are to describe candesartan cilexetil antihypertensive effects in terms of achieved blood pressure and hypertension control rates and the relationship between subject characteristics and antihypertensive efficacy, and between antihypertensive therapy (candesartan cilexetil dose and add-on treatments) and efficacy over a 1 year treatment period in hypertensive children ages 6 to \< 17 years; to describe growth in terms of height and weight in the study population; to describe change in neurocognition as assessed by the Full Scaled IQ score in a subset of study subjects; to determine the pharmacokinetics of candesartan in hypertensive paediatric subjects ages 6 to \< 17 years; and to describe safety including adverse events and adverse events necessitating study drug discontinuation including dose level and dose duration relationships and growth over a 1 year period in hypertensive children age 6 to \< 17 years.

Study identification

NCT ID
NCT00244595
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
235 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2003
Primary completion
Not listed
Completion
Oct 31, 2006
Last update posted
Dec 8, 2009

2003 – 2006

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
37
Facility City State ZIP Site status
Research Site Phoenix Arizona
Research Site Beverly Hills California
Research Site Los Angeles California
Research Site Madera California
Research Site Yuba City California
Research Site Newark Delaware
Research Site Wilmington Delaware
Research Site Miami Florida
Research Site Athens Georgia
Research Site Augusta Georgia
Research Site Chicago Illinois
Research Site Park Ridge Illinois
Research Site Louisville Kentucky
Research Site Ann Arbor Michigan
Research Site Jackson Mississippi
Research Site Port Gibson Mississippi
Research Site St Louis Missouri
Research Site Las Vegas Nevada
Research Site Paterson New Jersey
Research Site Brooklyn New York
Research Site New Hyde Park New York
Research Site The Bronx New York
Research Site Charlotte North Carolina
Research Site Winston-Salem North Carolina
Research Site Cincinnati Ohio
Research Site Cleveland Ohio
Research Site Columbus Ohio
Research Site Portland Oregon
Research Site Philadelphia Pennsylvania
Research Site Pittsburgh Pennsylvania
Research Site Charleston South Carolina
Research Site Beaumont Texas
Research Site Houston Texas
Research Site Salt Lake City Utah
Research Site Charlottesville Virginia
Research Site Norfolk Virginia
Research Site Charleston West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00244595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2009 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00244595 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →